Industry Research Reports

Home > Reports > Pharma & Healthcare > Urokinase- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032

Urokinase- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032

Industry: Pharma & Healthcare

Published Date: 2026-01-04

Pages: 110 Pages

Report ld: 5494929

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Industry Insights:

Urokinase Research：CAGR of 4.7% during the forecast period

Urokinase Market Size(US$)

CAGR 2026-2032

5.2%

Market Size,2032

USD 120

Million

Market Snapshot

Market Size in 2026 (Value)

US$ 88.53 million

Market Forecast in 2032(Value)

US$ 120 million

CAGR

5.2%

Years Considered

2021-2032

Base Year

2026

Forecast Period

2026-2032

Source: Secondary research, interviews with experts, and QYResearch analysis

The global market for Urokinase was estimated to be worth US$ 82.09 million in 2025 and is projected to reach US$ 120 million, growing at a CAGR of 5.2% from 2026 to 2032.

The potential shifts in the 2025 U.S. tariff framework pose substantial volatility risks to global markets. This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Urokinase cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Urokinase is a clot-dissolving medicine. It is a natural enzyme (a protein) that activates the body’s own fibrinolytic system by converting plasminogen into plasmin, and plasmin then breaks down fibrin, which is the “mesh” that holds a blood clot together. This is why urokinase is called a thrombolytic or “clot-buster.” The market for urokinase mainly includes injectable products (usually a sterile powder that is dissolved before use) that are given in hospitals, either through a vein or through a catheter directly to the clot area, depending on the indication and local practice. The clinical risk that shapes this market is also simple: because the drug dissolves clots, it can also weaken normal clotting at injury sites, so bleeding is the key safety concern and a major reason urokinase is used in controlled hospital settings.

A practical market definition should also include how urokinase is made, because that affects supply, regulatory burden, and cost. Urokinase products can differ by source. The U.S. Kinlytic label describes production from human neonatal kidney cells grown in tissue culture, and it explains extensive donor screening and virus testing/inactivation steps because it is derived from human source material. In contrast, some European product information describes urokinase that is extracted from human urine. These differences matter commercially: biologic sourcing and validation requirements make it harder for many manufacturers to enter, and they increase the importance of quality systems, change control, and reliable supply chains.

On the demand side, the most basic driver is that blood clots are common, and a subset of them are severe enough that rapid clot removal is lifesaving or limb-saving. The U.S. CDC says up to 900,000 people in the United States are affected by venous thromboembolism (VTE) each year, and VTE is linked to tens of thousands of deaths. Globally, cardiovascular diseases are still the leading cause of death, and they overlap with clot problems and high-risk hospital populations. These facts do not mean every clot patient needs urokinase. Most patients receive anticoagulants and supportive care, not thrombolytics. But they explain why hospitals continue to need a set of clot-management tools, including thrombolytic drugs, for the most urgent cases.

In 2025, global Urokinase production reached approximately 2736 BIU, with an average global market price of around US$ 30 per MIU. The global single-line production capacity ranges from 100 to 150 BIU per year. The industry's gross profit margin is approximately 25%-35%.

One of the clearest growth “pockets” for urokinase is catheter and access-device management. Modern medicine uses a large volume of central venous catheters for chemotherapy, nutrition, antibiotics, and dialysis. These devices can become blocked by thrombus or fibrin sheaths. In Europe, regulatory summaries describe urokinase use for clots in catheters or cannulae, which is essentially “catheter clearance.” Clinical literature on thrombolytic therapy for catheter occlusion discusses multiple agents and reports that thrombolytics can restore patency in a meaningful share of blocked catheters, with performance differences by drug and dosing strategy; this is a major reason hospitals keep thrombolytic protocols for catheter salvage. When catheter salvage works, it avoids line replacement, reduces procedure risk, and helps preserve access sites—especially important for dialysis and oncology patients. This clinical logic is also why companies publicly frame catheter clearance as an attractive commercial segment when they talk about bringing urokinase products back to market.

A second demand segment is catheter-directed thrombolysis (CDT) for limb-threatening peripheral arterial occlusion or extensive venous thrombosis, where drug is infused locally through a catheter rather than given as a full systemic infusion. Product information for urokinase in Europe explicitly describes acute peripheral arterial occlusions and notes that catheter-directed local lysis is the preferred method of administration for that scenario. More recent reviews also describe CDT as an effective endovascular method for thrombotic peripheral artery occlusions, while emphasizing the need for careful monitoring because bleeding and other complications are real. This creates a steady, procedure-linked demand for urokinase (and competing thrombolytics) in hospitals that perform vascular interventions. The market driver here is not only disease incidence; it is the expansion of interventional capability, better imaging, and more hospitals building vascular teams that can do “minimally invasive” clot removal rather than open surgery in selected patients.

At the same time, a major market trend is that urokinase is not the only clot-buster, and in some very large indications it has been replaced by other approaches. In acute ischemic stroke, for example, many regions use alteplase or tenecteplase, and mechanical thrombectomy has grown for large-vessel occlusions. In myocardial infarction, primary PCI has replaced thrombolysis in many systems where rapid catheterization is available. These shifts matter because they move thrombolytic use toward more specialized niches. In catheter clearance specifically, alteplase has strong clinical adoption in many settings, and reviews discuss its clearance rates and how other agents compare. So, one trend in the urokinase market is “narrower but deeper”: fewer broad, mass-market indications, but ongoing need in hospital procedures and device-related clots where protocols and economics favor certain agents.

Global key players of urokinase include Syner-Med, LIVZON, Wanhua Biochem, etc. The top three players hold a share about 50%.

This report provides a comprehensive view of the global market for Urokinase, covering total sales volume, sales revenue, pricing, the market share and ranking of key companies, along with analyses by region & country, by Type, and by Application.

The Urokinase market size, estimations, and forecasts are presented in terms of sales volume (BIU) and revenue ($ millions), with 2025 as the base year and historical and forecast data from 2021 to 2032. The report combines quantitative and qualitative analysis to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current marketplace, and make informed business decisions regarding Urokinase.

MARKET SEGMENTATION

By Company

Syner-Med
Wanhua Biochem
Jiangxi Haoran Bio-Pharma
Jiangsu Aidea Pharmaceutical
Techpool
Microbic Biosystems
LIVZON
Wuhan Humanwell Pharma
Tianjin Biochem Pharma

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Urokinase Powder
Urokinase Solution

Segment by Application

Hospital
Clinic
Others

Segment by Category

Pulmonary Embolism Thrombolysis
Deep Vein Thrombosis
Peripheral Arterial Occlusion Thrombolysis
Catheter / Cannula Occlusion Clearance
Others

Segment by Division

Systemic Infusion
Catheter-directed Thrombolysis (CDT)
Intracatheter Dwell / Lock Technique

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the scope of the report and the global market size (value, volume, and price). It also summarizes market dynamics and Recent Developments; identifies key drivers and restraints; outlines challenges and risks for manufacturers; reviews relevant industry policies and U.S. tariff implications.

Chapter 2: Provides a detailed analysis of the Urokinase manufacturers' competitive landscape—including pricing, sales and revenue shares, Recent Developments plans, and mergers and acquisitions (M&A).

Chapter 3: Analyzes market segmentation by Type, presenting the size and growth potential of each segment to help readers identify blue-ocean opportunities.

Chapter 4: Analyzes market segmentation by Application, presenting the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.

Chapter 5: Presents Urokinase sales and revenue at the regional level. It offers a quantitative assessment of market size and growth potential by region and summarizes market development, future prospects, addressable space, and country-level market size worldwide.

Chapter 6: Presents Urokinase sales and revenue at the country level. It provides segmented data by Type and by Application for each country/region.

Chapter 7: Profiles key players, detailing the main companies' product sales, revenue, pricing, gross margin, product portfolios, Recent Developments, etc.

Chapter 8: Analyzes the industry value chain, including upstream suppliers and downstream applications/customers.

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 Urokinase Product Introduction

1.2 Global Urokinase Market Size Forecast

1.2.1 Global Urokinase Sales Value (2021–2032)

1.2.2 Global Urokinase Sales Volume (2021–2032)

1.2.3 Global Urokinase Sales Price (2021–2032)

1.3 Urokinase Market Trends & Drivers

1.3.1 Urokinase Industry Trends

1.3.2 Urokinase Market Drivers & Opportunities

1.3.3 Urokinase Market Challenges

1.3.4 Urokinase Market Restraints

1.3.5 Impact of U.S. Tariffs

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Urokinase Players Revenue Ranking (2025)

2.2 Global Urokinase Revenue by Company (2021–2026)

2.3 Global Urokinase Sales Volume Ranking of Players (2025)

2.4 Global Urokinase Sales Volume by Company (2021–2026)

2.5 Global Urokinase Average Price by Company (2021–2026)

2.6 Key Manufacturers Urokinase Manufacturing Base and Headquarters

2.7 Key Manufacturers Urokinase Product Offerings

2.8 Key Manufacturers Start of Mass Production of Urokinase

2.9 Urokinase Market Competitive Analysis

2.9.1 Urokinase Market Concentration Rate (2021–2026)

2.9.2 Global 5 and 10 Largest Manufacturers by Urokinase Revenue in 2025

2.9.3 Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on Urokinase revenue, 2025

2.10 Mergers & Acquisitions and Expansion

3 Segmentation Urokinase Market Classification

3.1 Introduction by Type

3.1.1 Urokinase Powder

3.1.2 Urokinase Solution

3.1.3 Global Urokinase Sales Value by Type

3.1.3.1 Global Urokinase Sales Value by Type (2021 vs 2025 vs 2032)

3.1.3.2 Global Urokinase Sales Value, by Type (2021–2032)

3.1.3.3 Global Urokinase Sales Value, by Type (%), 2021–2032

3.1.4 Global Urokinase Sales Volume by Type

3.1.4.1 Global Urokinase Sales Volume by Type (2021 vs 2025 vs 2032)

3.1.4.2 Global Urokinase Sales Volume, by Type (2021–2032)

3.1.4.3 Global Urokinase Sales Volume, by Type (%), 2021–2032

3.1.5 Global Urokinase Average Price by Type (2021–2032)

3.2 Introduction by Clinical Use

3.2.1 Pulmonary Embolism Thrombolysis

3.2.2 Deep Vein Thrombosis

3.2.3 Peripheral Arterial Occlusion Thrombolysis

3.2.4 Catheter / Cannula Occlusion Clearance

3.2.5 Others

3.2.6 Global Urokinase Sales Value by Clinical Use

3.2.6.1 Global Urokinase Sales Value by Clinical Use (2021 vs 2025 vs 2032)

3.2.6.2 Global Urokinase Sales Value, by Clinical Use (2021–2032)

3.2.6.3 Global Urokinase Sales Value, by Clinical Use (%), 2021–2032

3.2.7 Global Urokinase Sales Volume by Clinical Use

3.2.7.1 Global Urokinase Sales Volume by Clinical Use (2021 vs 2025 vs 2032)

3.2.7.2 Global Urokinase Sales Volume, by Clinical Use (2021–2032)

3.2.7.3 Global Urokinase Sales Volume, by Clinical Use (%), 2021–2032

3.2.8 Global Urokinase Average Price by Clinical Use (2021–2032)

3.3 Introduction by Administration Approach

3.3.1 Systemic Infusion

3.3.2 Catheter-directed Thrombolysis (CDT)

3.3.3 Intracatheter Dwell / Lock Technique

3.3.4 Global Urokinase Sales Value by Administration Approach

3.3.4.1 Global Urokinase Sales Value by Administration Approach (2021 vs 2025 vs 2032)

3.3.4.2 Global Urokinase Sales Value, by Administration Approach (2021–2032)

3.3.4.3 Global Urokinase Sales Value, by Administration Approach (%), 2021–2032

3.3.5 Global Urokinase Sales Volume by Administration Approach

3.3.5.1 Global Urokinase Sales Volume by Administration Approach (2021 vs 2025 vs 2032)

3.3.5.2 Global Urokinase Sales Volume, by Administration Approach (2021–2032)

3.3.5.3 Global Urokinase Sales Volume, by Administration Approach (%), 2021–2032

3.3.6 Global Urokinase Average Price by Administration Approach (2021–2032)

3.4 Introduction by Purity

3.4.1 Standard Clinical Grade

3.4.2 High-purity / Low-impurity Grade

3.4.3 Low Endotoxin / Low Bioburden Specifications

3.4.4 Global Urokinase Sales Value by Purity

3.4.4.1 Global Urokinase Sales Value by Purity (2021 vs 2025 vs 2032)

3.4.4.2 Global Urokinase Sales Value, by Purity (2021–2032)

3.4.4.3 Global Urokinase Sales Value, by Purity (%), 2021–2032

3.4.5 Global Urokinase Sales Volume by Purity

3.4.5.1 Global Urokinase Sales Volume by Purity (2021 vs 2025 vs 2032)

3.4.5.2 Global Urokinase Sales Volume, by Purity (2021–2032)

3.4.5.3 Global Urokinase Sales Volume, by Purity (%), 2021–2032

3.4.6 Global Urokinase Average Price by Purity (2021–2032)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital

4.1.2 Clinic

4.1.3 Others

4.2 Global Urokinase Sales Value by Application

4.2.1 Global Urokinase Sales Value by Application (2021 vs 2025 vs 2032)

4.2.2 Global Urokinase Sales Value, by Application (2021–2032)

4.2.3 Global Urokinase Sales Value, by Application (%), 2021–2032

4.3 Global Urokinase Sales Volume by Application

4.3.1 Global Urokinase Sales Volume by Application (2021 vs 2025 vs 2032)

4.3.2 Global Urokinase Sales Volume, by Application (2021–2032)

4.3.3 Global Urokinase Sales Volume, by Application (%), 2021–2032

4.4 Global Urokinase Average Price by Application (2021–2032)

5 Segmentation by Region

5.1 Global Urokinase Sales Value by Region

5.1.1 Global Urokinase Sales Value by Region: 2021 vs 2025 vs 2032

5.1.2 Global Urokinase Sales Value by Region (2021–2026)

5.1.3 Global Urokinase Sales Value by Region (2027–2032)

5.1.4 Global Urokinase Sales Value by Region (%), 2021–2032

5.2 Global Urokinase Sales Volume by Region

5.2.1 Global Urokinase Sales Volume by Region: 2021 vs 2025 vs 2032

5.2.2 Global Urokinase Sales Volume by Region (2021–2026)

5.2.3 Global Urokinase Sales Volume by Region (2027–2032)

5.2.4 Global Urokinase Sales Volume by Region (%), 2021–2032

5.3 Global Urokinase Average Price by Region (2021–2032)

5.4 North America

5.4.1 North America Urokinase Sales Value, 2021–2032

5.4.2 North America Urokinase Sales Value by Country (%), 2025 vs 2032

5.5 Europe

5.5.1 Europe Urokinase Sales Value, 2021–2032

5.5.2 Europe Urokinase Sales Value by Country (%), 2025 vs 2032

5.6 Asia Pacific

5.6.1 Asia Pacific Urokinase Sales Value, 2021–2032

5.6.2 Asia Pacific Urokinase Sales Value by Region (%), 2025 vs 2032

5.7 South America

5.7.1 South America Urokinase Sales Value, 2021–2032

5.7.2 South America Urokinase Sales Value by Country (%), 2025 vs 2032

5.8 Middle East & Africa

5.8.1 Middle East & Africa Urokinase Sales Value, 2021–2032

5.8.2 Middle East & Africa Urokinase Sales Value by Country (%), 2025 vs 2032

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Urokinase Sales Value Growth Trends, 2021 vs 2025 vs 2032

6.2 Key Countries/Regions Urokinase Sales Value and Sales Volume

6.2.1 Key Countries/Regions Urokinase Sales Value, 2021–2032

6.2.2 Key Countries/Regions Urokinase Sales Volume, 2021–2032

6.3 United States

6.3.1 United States Urokinase Sales Value, 2021–2032

6.3.2 United States Urokinase Sales Value by Type (%), 2025 vs 2032

6.3.3 United States Urokinase Sales Value by Application, 2025 vs 2032

6.4 Europe

6.4.1 Europe Urokinase Sales Value, 2021–2032

6.4.2 Europe Urokinase Sales Value by Type (%), 2025 vs 2032

6.4.3 Europe Urokinase Sales Value by Application, 2025 vs 2032

6.5 China

6.5.1 China Urokinase Sales Value, 2021–2032

6.5.2 China Urokinase Sales Value by Type (%), 2025 vs 2032

6.5.3 China Urokinase Sales Value by Application, 2025 vs 2032

6.6 Japan

6.6.1 Japan Urokinase Sales Value, 2021–2032

6.6.2 Japan Urokinase Sales Value by Type (%), 2025 vs 2032

6.6.3 Japan Urokinase Sales Value by Application, 2025 vs 2032

6.7 South Korea

6.7.1 South Korea Urokinase Sales Value, 2021–2032

6.7.2 South Korea Urokinase Sales Value by Type (%), 2025 vs 2032

6.7.3 South Korea Urokinase Sales Value by Application, 2025 vs 2032

6.8 Southeast Asia

6.8.1 Southeast Asia Urokinase Sales Value, 2021–2032

6.8.2 Southeast Asia Urokinase Sales Value by Type (%), 2025 vs 2032

6.8.3 Southeast Asia Urokinase Sales Value by Application, 2025 vs 2032

6.9 India

6.9.1 India Urokinase Sales Value, 2021–2032

6.9.2 India Urokinase Sales Value by Type (%), 2025 vs 2032

6.9.3 India Urokinase Sales Value by Application, 2025 vs 2032

7 Company Profiles

7.1 Syner-Med

7.1.1 Syner-Med Company Information

7.1.2 Syner-Med Introduction and Business Overview

7.1.3 Syner-Med Urokinase Sales, Revenue, Price and Gross Margin (2021–2026)

7.1.4 Syner-Med Urokinase Product Offerings

7.1.5 Syner-Med Recent Developments

7.2 Wanhua Biochem

7.2.1 Wanhua Biochem Company Information

7.2.2 Wanhua Biochem Introduction and Business Overview

7.2.3 Wanhua Biochem Urokinase Sales, Revenue, Price and Gross Margin (2021–2026)

7.2.4 Wanhua Biochem Urokinase Product Offerings

7.2.5 Wanhua Biochem Recent Developments

7.3 Jiangxi Haoran Bio-Pharma

7.3.1 Jiangxi Haoran Bio-Pharma Company Information

7.3.2 Jiangxi Haoran Bio-Pharma Introduction and Business Overview

7.3.3 Jiangxi Haoran Bio-Pharma Urokinase Sales, Revenue, Price and Gross Margin (2021–2026)

7.3.4 Jiangxi Haoran Bio-Pharma Urokinase Product Offerings

7.3.5 Jiangxi Haoran Bio-Pharma Recent Developments

7.4 Jiangsu Aidea Pharmaceutical

7.4.1 Jiangsu Aidea Pharmaceutical Company Information

7.4.2 Jiangsu Aidea Pharmaceutical Introduction and Business Overview

7.4.3 Jiangsu Aidea Pharmaceutical Urokinase Sales, Revenue, Price and Gross Margin (2021–2026)

7.4.4 Jiangsu Aidea Pharmaceutical Urokinase Product Offerings

7.4.5 Jiangsu Aidea Pharmaceutical Recent Developments

7.5 Techpool

7.5.1 Techpool Company Information

7.5.2 Techpool Introduction and Business Overview

7.5.3 Techpool Urokinase Sales, Revenue, Price and Gross Margin (2021–2026)

7.5.4 Techpool Urokinase Product Offerings

7.5.5 Techpool Recent Developments

7.6 Microbic Biosystems

7.6.1 Microbic Biosystems Company Information

7.6.2 Microbic Biosystems Introduction and Business Overview

7.6.3 Microbic Biosystems Urokinase Sales, Revenue, Price and Gross Margin (2021–2026)

7.6.4 Microbic Biosystems Urokinase Product Offerings

7.6.5 Microbic Biosystems Recent Developments

7.7 LIVZON

7.7.1 LIVZON Company Information

7.7.2 LIVZON Introduction and Business Overview

7.7.3 LIVZON Urokinase Sales, Revenue, Price and Gross Margin (2021–2026)

7.7.4 LIVZON Urokinase Product Offerings

7.7.5 LIVZON Recent Developments

7.8 Wuhan Humanwell Pharma

7.8.1 Wuhan Humanwell Pharma Company Information

7.8.2 Wuhan Humanwell Pharma Introduction and Business Overview

7.8.3 Wuhan Humanwell Pharma Urokinase Sales, Revenue, Price and Gross Margin (2021–2026)

7.8.4 Wuhan Humanwell Pharma Urokinase Product Offerings

7.8.5 Wuhan Humanwell Pharma Recent Developments

7.9 Tianjin Biochem Pharma

7.9.1 Tianjin Biochem Pharma Company Information

7.9.2 Tianjin Biochem Pharma Introduction and Business Overview

7.9.3 Tianjin Biochem Pharma Urokinase Sales, Revenue, Price and Gross Margin (2021–2026)

7.9.4 Tianjin Biochem Pharma Urokinase Product Offerings

7.9.5 Tianjin Biochem Pharma Recent Developments

8 Industry Chain Analysis

8.1 Urokinase Industrial Chain

8.2 Urokinase Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Key Suppliers of Raw Materials

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customer Analysis)

8.5 Sales Model and Sales Channelss

8.5.1 Urokinase Sales Model

8.5.2 Sales Channels

8.5.3 Urokinase Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Urokinase Market Trends

Table 2. Urokinase Market Drivers & Opportunities

Table 3. Urokinase Market Challenges

Table 4. Urokinase Market Restraints

List of Figures

Figure 1. Urokinase Product Picture

Figure 2. Global Urokinase Sales Value, 2021 vs 2025 vs 2032 (US$ Million)

Figure 3. Global Urokinase Sales Value (US$ Million), 2021–2032

Figure 4. Global Urokinase Sales Volume (BIU), 2021–2032

Figure 5. Global Urokinase Sales Price (US$/MIU), 2021–2032

Figure 6. Urokinase Report Years Considered

Figure 7. Global Urokinase Players Revenue Ranking (US$ Million), 2025

Figure 8. Global Urokinase Sales Volume Ranking of Players (BIU), 2025

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Urokinase Revenue in 2025

Figure 10. Urokinase Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 11. Urokinase Powder Picture

Figure 12. Urokinase Solution Picture

Figure 13. Global Urokinase Sales Value by Type (US$ Million), 2021 vs 2025 vs 2032

Figure 14. Global Urokinase Sales Value Market Share by Type, 2025 & 2032

Figure 15. Global Urokinase Sales Volume by Type (BIU), 2021 vs 2025 vs 2032

Figure 16. Global Urokinase Sales Volume Market Share by Type, 2025 & 2032

Figure 17. Global Urokinase Price by Type (US$/MIU), 2021–2032

Figure 18. Pulmonary Embolism Thrombolysis Picture

Figure 19. Deep Vein Thrombosis Picture

Figure 20. Peripheral Arterial Occlusion Thrombolysis Picture

Figure 21. Catheter / Cannula Occlusion Clearance Picture

Figure 22. Others Picture

Figure 23. Global Urokinase Sales Value by Clinical Use (US$ Million), 2021 vs 2025 vs 2032

Figure 24. Global Urokinase Sales Value Market Share by Clinical Use, 2025 & 2032

Figure 25. Global Urokinase Sales Volume by Clinical Use (BIU), 2021 vs 2025 vs 2032

Figure 26. Global Urokinase Sales Volume Market Share by Clinical Use, 2025 & 2032

Figure 27. Global Urokinase Price by Clinical Use (US$/MIU), 2021–2032

Figure 28. Systemic Infusion Picture

Figure 29. Catheter-directed Thrombolysis (CDT) Picture

Figure 30. Intracatheter Dwell / Lock Technique Picture

Figure 31. Global Urokinase Sales Value by Administration Approach (US$ Million), 2021 vs 2025 vs 2032

Figure 32. Global Urokinase Sales Value Market Share by Administration Approach, 2025 & 2032

Figure 33. Global Urokinase Sales Volume by Administration Approach (BIU), 2021 vs 2025 vs 2032

Figure 34. Global Urokinase Sales Volume Market Share by Administration Approach, 2025 & 2032

Figure 35. Global Urokinase Price by Administration Approach (US$/MIU), 2021–2032

Figure 36. Standard Clinical Grade Picture

Figure 37. High-purity / Low-impurity Grade Picture

Figure 38. Low Endotoxin / Low Bioburden Specifications Picture

Figure 39. Global Urokinase Sales Value by Purity (US$ Million), 2021 vs 2025 vs 2032

Figure 40. Global Urokinase Sales Value Market Share by Purity, 2025 & 2032

Figure 41. Global Urokinase Sales Volume by Purity (BIU), 2021 vs 2025 vs 2032

Figure 42. Global Urokinase Sales Volume Market Share by Purity, 2025 & 2032

Figure 43. Global Urokinase Price by Purity (US$/MIU), 2021–2032

Figure 44. Product Picture of Hospital

Figure 45. Product Picture of Clinic

Figure 46. Product Picture of Others

Figure 47. Global Urokinase Sales Value by Application (US$ Million), 2021 vs 2025 vs 2032

Figure 48. Global Urokinase Sales Value Market Share by Application, 2025 & 2032

Figure 49. Global Urokinase Sales Volume by Application (BIU), 2021 vs 2025 vs 2032

Figure 50. Global Urokinase Sales Volume Market Share by Application, 2025 & 2032

Figure 51. Global Urokinase Price by Application (US$/MIU), 2021–2032

Figure 52. North America Urokinase Sales Value (US$ Million), 2021–2032

Figure 53. North America Urokinase Sales Value by Country (%), 2025 vs 2032

Figure 54. Europe Urokinase Sales Value (US$ Million), 2021–2032

Figure 55. Europe Urokinase Sales Value by Country (%), 2025 vs 2032

Figure 56. Asia Pacific Urokinase Sales Value (US$ Million), 2021–2032

Figure 57. Asia Pacific Urokinase Sales Value by Region (%), 2025 vs 2032

Figure 58. South America Urokinase Sales Value (US$ Million), 2021–2032

Figure 59. South America Urokinase Sales Value by Country (%), 2025 vs 2032

Figure 60. Middle East & Africa Urokinase Sales Value (US$ Million), 2021–2032

Figure 61. Middle East & Africa Urokinase Sales Value by Country (%), 2025 vs 2032

Figure 62. Key Countries/Regions Urokinase Sales Value (%), 2021–2032

Figure 63. Key Countries/Regions Urokinase Sales Volume (%), 2021–2032

Figure 64. United States Urokinase Sales Value (US$ Million), 2021–2032

Figure 65. United States Urokinase Sales Value by Type (%), 2025 vs 2032

Figure 66. United States Urokinase Sales Value by Application (%), 2025 vs 2032

Figure 67. Europe Urokinase Sales Value (US$ Million), 2021–2032

Figure 68. Europe Urokinase Sales Value by Type (%), 2025 vs 2032

Figure 69. Europe Urokinase Sales Value by Application (%), 2025 vs 2032

Figure 70. China Urokinase Sales Value (US$ Million), 2021–2032

Figure 71. China Urokinase Sales Value by Type (%), 2025 vs 2032

Figure 72. China Urokinase Sales Value by Application (%), 2025 vs 2032

Figure 73. Japan Urokinase Sales Value (US$ Million), 2021–2032

Figure 74. Japan Urokinase Sales Value by Type (%), 2025 vs 2032

Figure 75. Japan Urokinase Sales Value by Application (%), 2025 vs 2032

Figure 76. South Korea Urokinase Sales Value (US$ Million), 2021–2032

Figure 77. South Korea Urokinase Sales Value by Type (%), 2025 vs 2032

Figure 78. South Korea Urokinase Sales Value by Application (%), 2025 vs 2032

Figure 79. Southeast Asia Urokinase Sales Value (US$ Million), 2021–2032

Figure 80. Southeast Asia Urokinase Sales Value by Type (%), 2025 vs 2032

Figure 81. Southeast Asia Urokinase Sales Value by Application (%), 2025 vs 2032

Figure 82. India Urokinase Sales Value (US$ Million), 2021–2032

Figure 83. India Urokinase Sales Value by Type (%), 2025 vs 2032

Figure 84. India Urokinase Sales Value by Application (%), 2025 vs 2032

Figure 85. Urokinase Industrial Chain

Figure 86. Urokinase Manufacturing Cost Structure

Figure 87. Channels of Distribution (Direct Sales, and Distribution)

Figure 88. Bottom-up and Top-down Approaches for This Report

Figure 89. Data Triangulation

Figure 90. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

What is the annual compound growth rate of the global Urokinase market size from 2026 to 2032? zhanKai

The annual compound growth rate of the global Urokinase market is 5.2% 2026 to 2032.

Which companies rank high in the global Urokinase market? shouQi

What was the global market size of Urokinase in 2032? shouQi

What was the global market size of Urokinase in 2026? shouQi

Which region is expected to have the highest market share? shouQi

Related Reports

Global Urokinase Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Urokinase market size was US$ 82.09 million in 2025 and is forecast to reach a readjusted size of US$ 120 million by 2032 with a CAGR of 5.2% during the forecast period 2026-2032.
Published Date: 2026-01-04
Pages: 77
USD 4250.00
(Single User License)
Global Urokinase Market Research Report 2026
The global Urokinase market was valued at US$ 82.09 million in 2025 and is anticipated to reach US$ 120 million by 2032, at a CAGR of 5.2% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 116
USD 2900.00
(Single User License)
Global Urokinase Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Urokinase market is projected to grow from US$ 49.8 million in 2024 to US$ 70.6 million by 2031, at a CAGR of 5.2% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-09-11
Pages: 147
USD 4900.00
(Single User License)
Global Urokinase Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Urokinase was estimated to be worth US$ 49.8 million and is forecast to reach approximately US$ 70.6 million by 2031 with a CAGR of 5.2% during the forecast period 2025-2031.
Published Date: 2025-03-28
Pages: 121
USD 5900.00
(Single User License)
Global Urokinase Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Urokinase market size was US$ 49.8 million in 2024 and is forecast to a readjusted size of US$ 70.6 million by 2031 with a CAGR of 5.2% during the forecast period 2025-2031.
Published Date: 2025-03-19
Pages: 79
USD 4250.00
(Single User License)
Urokinase- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Urokinase was estimated to be worth US$ 49.8 million in 2024 and is forecast to a readjusted size of US$ 70.6 million by 2031 with a CAGR of 5.2% during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 95
USD 3950.00
(Single User License)
Global Urokinase Market Research Report 2025
The global market for Urokinase was valued at US$ 49.8 million in the year 2024 and is projected to reach a revised size of US$ 70.6 million by 2031, growing at a CAGR of 5.2% during the forecast period.
Published Date: 2025-01-16
Pages: 79
USD 2900.00
(Single User License)
Global Urokinase Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in 1947. Urokinase was originally isolated from human urine, and it is also present in the blood and in the extracellular matrix of many tissues. The primary physiological substrate of this enzyme is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin.
Published Date: 2024-04-17
Pages: 142
USD 5600.00
(Single User License)
Global Urokinase Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in 1947. Urokinase was originally isolated from human urine, and it is also present in the blood and in the extracellular matrix of many tissues. The primary physiological substrate of this enzyme is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin.
Published Date: 2024-04-16
Pages: 137
USD 5900.00
(Single User License)
Global Urokinase Market Insights, Forecast to 2030
Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in 1947. Urokinase was originally isolated from human urine, and it is also present in the blood and in the extracellular matrix of many tissues. The primary physiological substrate of this enzyme is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin.
Published Date: 2024-04-07
Pages: 89
USD 4900.00
(Single User License)

Global Urokinase Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Urokinase market size was US$ 82.09 million in 2025 and is forecast to reach a readjusted size of US$ 120 million by 2032 with a CAGR of 5.2% during the forecast period 2026-2032.
Published: 2026-01-04
Pages: 77
USD 4250.00 (Single User License)
Global Urokinase Market Research Report 2026
The global Urokinase market was valued at US$ 82.09 million in 2025 and is anticipated to reach US$ 120 million by 2032, at a CAGR of 5.2% from 2026 to 2032.
Published: 2026-01-04
Pages: 116
USD 2900.00 (Single User License)
Global Urokinase Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Urokinase market is projected to grow from US$ 49.8 million in 2024 to US$ 70.6 million by 2031, at a CAGR of 5.2% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-09-11
Pages: 147
USD 4900.00 (Single User License)
Global Urokinase Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Urokinase was estimated to be worth US$ 49.8 million and is forecast to reach approximately US$ 70.6 million by 2031 with a CAGR of 5.2% during the forecast period 2025-2031.
Published: 2025-03-28
Pages: 121
USD 5900.00 (Single User License)
Global Urokinase Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Urokinase market size was US$ 49.8 million in 2024 and is forecast to a readjusted size of US$ 70.6 million by 2031 with a CAGR of 5.2% during the forecast period 2025-2031.
Published: 2025-03-19
Pages: 79
USD 4250.00 (Single User License)
Urokinase- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Urokinase was estimated to be worth US$ 49.8 million in 2024 and is forecast to a readjusted size of US$ 70.6 million by 2031 with a CAGR of 5.2% during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 95
USD 3950.00 (Single User License)
Global Urokinase Market Research Report 2025
The global market for Urokinase was valued at US$ 49.8 million in the year 2024 and is projected to reach a revised size of US$ 70.6 million by 2031, growing at a CAGR of 5.2% during the forecast period.
Published: 2025-01-16
Pages: 79
USD 2900.00 (Single User License)
Global Urokinase Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in 1947. Urokinase was originally isolated from human urine, and it is also present in the blood and in the extracellular matrix of many tissues. The primary physiological substrate of this enzyme is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin.
Published: 2024-04-17
Pages: 142
USD 5600.00 (Single User License)
Global Urokinase Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in 1947. Urokinase was originally isolated from human urine, and it is also present in the blood and in the extracellular matrix of many tissues. The primary physiological substrate of this enzyme is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin.
Published: 2024-04-16
Pages: 137
USD 5900.00 (Single User License)
Global Urokinase Market Insights, Forecast to 2030
Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in 1947. Urokinase was originally isolated from human urine, and it is also present in the blood and in the extracellular matrix of many tissues. The primary physiological substrate of this enzyme is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin.
Published: 2024-04-07
Pages: 89
USD 4900.00 (Single User License)